Top

Cancer Cell International

Published in:

01-12-2020 | Metastasis | Primary research

Suppression of CCT3 inhibits the proliferation and migration in breast cancer cells

Authors: Gang Xu, Shanshan Bu, Xiushen Wang, He Zhang, Hong Ge

Published in: Cancer Cell International | Issue 1/2020

Abstract

Background

CCT3 is a subunit of chaperonin-containing TCP-1 (CCT), which folds many proteins involved in cancer development and plays an important role in many cancers. However, the role of CCT3 in breast cancer is still unclear.

Methods

CCT3 expression was knocked down by transfecting breast cancer cells with lentiviral shRNA. The proliferation of breast cancer cells (HCC1937 and MDA-MB-231) was detected by Celigo image cytometry and MTT assay, the migration of the cells was measured by Transwell analysis, cell cycle distribution and apoptosis was detected by flow cytometry, and changes in signal transduction proteins were detected by western blot analysis.

Results

The expression of CCT3 was significantly suppressed by transduction with lentiviral shRNA; CCT3 knockdown significantly reduced the proliferation and metastasis ability of breast cancer cells (HCC 1937 and MDA-MB-231), increased the proportion of cells in S phase, and decreased the proportion of cells in G1 phase compared to those in shControl cells. There was no significant change in the number of cells in the G2/M phase. Apoptosis analysis showed that knockdown of CCT3 induced apoptosis in breast cancer cells. Western blot analysis showed that the expression of many signal transduction proteins was changed after suppression of CCT3. A rescue experiment showed that overexpression of NFκB-p65 rescued the cell proliferation and migration affected by CCT3 in breast cancer cells.

Conclusion

CCT3 is closely related to the proliferation and migration of breast cancer and may be a novel therapeutic target.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRef

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J, Cardoso F. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66. https://doi.org/10.1038/s41572-019-0111-2.CrossRefPubMed

Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, AguilarLopez B, Barrios CH, Bergh J, et al. ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018. https://doi.org/10.1093/annonc/mdy192.CrossRefPubMedPubMedCentral

Stoldt V, Rademacher F, Kehren V, Ernst JF, Pearce DA, Sherman F. Review: the CCT eukaryotic chaperonin subunits of Saccharomyces cerevisiae and other yeasts. Yeast. 1996;12:523–9.CrossRef

Valpuesta JM, Martin-Benito J, Gomez-Puertas P, Carrascosa JL, Willison KR. Structure and function of a protein folding machine: the eukaryotic cytosolic chaperonin CCT. FEBS Lett. 2002;529:11–6.CrossRef

Karen IB, Julie G. Activities of the chaperonin containing TCP-1 (CCT): implications for cell cycle progression and cytoskeletal organisation. Cell Stress Chaperones. 2009;14(1):23–31.CrossRef

Qian EN, Han SY, Ding SZ, Lv X. Expression and diagnostic value of CCT3 and IQGAP3 in hepatocellular carcinoma. Cancer Cell Int. 2016;16:55. https://doi.org/10.1186/s12935-016-0332-3.CrossRefPubMedPubMedCentral

Hou Jia-Yin, Hua-Yu Wu, He Rong-Quan, Lin Peng, Dang Yi-Wu, Chen Gang. Clinical and prognostic value of chaperonin containing T-complex 1 subunit 3 in hepatocellular carcinoma: a study based on microarray and RNA-sequencing with 4272 cases. Pathol Res Pract. 2019;215(1):177–94.CrossRef

Zhang Y, Wang Y, Wei Y, Wu J, Zhang P, Shen S, Saiyin H, Wumaier R, Yang X, Wang C, et al. Molecular chaperone CCT3 supports proper mitotic progression and cell proliferation in hepatocellular carcinoma cells. Cancer Lett. 2016;372(1):101–9.CrossRef

10.

Li LJ, Zhang LS, Han ZJ, He ZY, Chen H, Li YM. Chaperonin containing TCP-1 subunit 3 is critical for gastric cancer growth. Oncotarget. 2017;8(67):111470–81.CrossRef

11.

Shi XH, Cheng SS, Wang WX. Suppression of CCT3 inhibits malignant proliferation of human papillary thyroid carcinoma cell. Oncol Lett. 2018;15(6):9202–8.PubMedPubMedCentral

12.

Qian TT, Cui LZ, Liu Y, Cheng ZH, Quan L, Zeng TS, Huang WH, Dai YF, Chen JH, Liu L. High expression of chaperonin-containing TCP1 subunit 3 may induce dismal prognosis in multiple myeloma. Pharmacogenom J. 2020. https://doi.org/10.1038/s41397-019-0145-6.10.1038/s41397-019-0145-6.CrossRef

13.

Bassiouni R, Nemec KN, Iketani A, Flores O, Showalter A, Khaled AS, Vishnubhotla P, Sprung RW Jr, Kaittanis C, Perez JM, et al. Chaperonin containing TCP-1 protein level in breast cancer cells predicts therapeutic application of a cytotoxic peptide. Clin Cancer Res. 2016;22(17):4366–79. https://doi.org/10.1158/1078-0432.CCR-15-2502.CrossRefPubMedPubMedCentral

14.

Showalter AE, Martini AC, Nierenberg D, Hosang K, Fahmi NA, Gopalan P, Khaled AS, Zhang W, Khaled AR. Investigating Chaperonin-Containing TCP-1 subunit 2 as an essential component of the chaperonin complex for tumorigenesis. Sci Rep. 2020;10(1):798. https://doi.org/10.1038/s41598-020-57602-w.CrossRefPubMedPubMedCentral

15.

Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. https://doi.org/10.1001/jama.2018.19323.CrossRefPubMed

16.

Ribnikar D, Volovat SR, Cardoso F. Targeting CDK4/6 pathways and beyond in breast cancer. Breast. 2019;43:8–17. https://doi.org/10.1016/j.breast.2018.10.001.CrossRefPubMed

17.

Sharma VR, Gupta GK, Sharma AK, Batra N, Sharma DK, Joshi A, Sharma AK. PI3K/Akt/mTOR intracellular pathway and breast cancer: factors, mechanism and regulation. Curr Pharm Des. 2017;23(11):1633–8. https://doi.org/10.2174/1381612823666161116125218.CrossRefPubMed

18.

Sternlicht H, Farr GW, Sternlicht ML, Driscoll JK, Willison KR, Yaffe MB. The t-complex polypeptide 1 complex is a chaperonin for tubulin and actin in vivo. Proc Natl Acad Sci. 1993;90:9422–6. https://doi.org/10.1073/pnas.90.20.9422.CrossRefPubMed

19.

Willison KR. The substrate specificity of eukaryotic cytosolic chaperonin CCT. Philos Trans R Soc Lond B Biol Sci. 2018;373(1749):20170192. https://doi.org/10.1098/rstb.2017.0192.CrossRefPubMedPubMedCentral

20.

Olson MF, Sahai E. The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis. 2009;26:273–87.CrossRef

21.

Zhao M, Spiess M, Johansson HJ, Olofsson H, Hu J, Lehtio J, Stromblad S. Identification of the PAK4 interactome reveals PAK4 phosphorylation of N-WASP and promotion of Arp2/3-dependent actin polymerization. Oncotarget. 2017;8:77061–74.CrossRef

22.

Brackley KI, Grantham J. Interactions between the actin filament capping and severing protein gelsolin and the molecular chaperone CCT: evidence for nonclassical substrate interactions. Cell Stress Chaperones. 2011;16:173–9.CrossRef

23.

Cui X, Hu ZP, Li Z, Gao PJ, Zhu JY. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma. World J Gastroenterol. 2015;21(28):8588–604. https://doi.org/10.3748/wjg.v21.i28.8588.CrossRefPubMedPubMedCentral

24.

Liu YJ, Chang YJ, Kuo YT, Liang PH. Targeting β-tubulin/CCT-β complex induces apoptosis and suppresses migration and invasion of highly metastatic lung adenocarcinom. Carcinogenesis. 2019. https://doi.org/10.1093/carcin/bgz137.CrossRefPubMedPubMedCentral

25.

Yang X, Ren H, Shao Y, Sun Y, Zhang L, Li H, Zhang X, Yang X, Yu W, Fu J. Chaperonin-containing T-complex protein 1 subunit 8 promotes cell migration and invasion in human esophageal squamous cell carcinoma by regulating α-actin and β-tubulin expression. Int J Oncol. 2018;52(6):2021–30. https://doi.org/10.3892/ijo.2018.4335.CrossRefPubMed

26.

Grantham J, Brackley KI, Willison KR. Substantial CCT activity is required for cell cycle progression and cytoskeletal organization in mammalian cells. Exp Cell Res. 2006;312(12):2309–24. https://doi.org/10.1016/j.yexcr.2006.03.028.CrossRefPubMed

27.

Yokota S, Yanagi H, Yura T, Kubota H. Cytosolic chaperonin is upregulated during cell growth. Preferential expression and binding to tubulin at G(1)/S transition through early S phase. J Biol Chem. 1999;274:37070–8.CrossRef

28.

Camasses A, Bogdanova A, Shevchenko A, Zachariae W. The CCT chaperonin promotes activation of the anaphase-promoting complex through the generation of functional Cdc20. Mol Cell. 2003;12:87–100.CrossRef

29.

Kadam CY, Abhang SA. Apoptosis markers in breast cancer therapy. Adv Clin Chem. 2016;74:143–93. https://doi.org/10.1016/bs.acc.2015.12.003.CrossRefPubMed

30.

Harley ME, Allan LA, Sanderson HS, Clarke PR. Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J. 2010;29(14):2407–20. https://doi.org/10.1038/emboj.2010.112.CrossRefPubMedPubMedCentral

31.

Wan L, Tan M, Yang J, Inuzuka H, Dai X, Wu T, Liu J, Shaik S, Chen G, Deng J, et al. APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction. Dev Cell. 2014;29(4):377–91. https://doi.org/10.1016/j.devcel.2014.04.022.CrossRefPubMedPubMedCentral

32.

Wang X, Simpson ER, Brown KA. p53: protection against tumor growth beyond effects on cell cycle and apoptosis. Cancer Res. 2015;75(23):5001–7. https://doi.org/10.1158/0008-5472.CAN-15-0563.CrossRefPubMed

33.

Kasembeli M, Lau WC, Roh SH, Echkols TK, Frydman J, Chiu W, Tweady DJ. Modulation of STAT3 folding and function by TRiC/CCT chaperonin. PLoS Biol. 2014;12(4):e1001844. https://doi.org/10.1371/journal.pbio.1001844.CrossRefPubMedPubMedCentral

34.

Fusella F, Seclì L, Busso E, Krepelova A, Moiso E, Rocca S, Conti L, Annaratone L, Rubinetto C, Mello-Grand M, et al. The IKK/NF-κB signaling pathway requires Morgana to drive breast cancer metastasis. Nat Commun. 2017;8(1):1636. https://doi.org/10.1038/s41467-017-01829-1.CrossRefPubMedPubMedCentral

35.

Zhang YC, Huo FC, Wei LL, Gong CC, Pan YJ, Mou J, Pei DS. PAK5-mediated phosphorylation and nuclear translocation of NF-κB-p65 promotes breast cancer cell proliferation in vitro and in vivo. J Exp Clin Cancer Res. 2017;36(1):146. https://doi.org/10.1186/s13046-017-0610-5.CrossRefPubMedPubMedCentral

36.

Ma C, Zu X, Liu K, Bode AM, Dong Z, Liu Z, Kim DJ. Knockdown of pyruvate kinase M inhibits cell growth and migration by reducing NF-kB activity in triple-negative breast cancer cells. Mol Cells. 2019;42(9):628–36. https://doi.org/10.14348/molcells.2019.0038.CrossRefPubMedPubMedCentral

Title: Suppression of CCT3 inhibits the proliferation and migration in breast cancer cells
Authors: Gang Xu
Shanshan Bu
Xiushen Wang
He Zhang
Hong Ge
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Metastasis
Breast Cancer
Breast Cancer
Published in: Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-020-01314-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Construction of a circRNA-miRNA-mRNA network based on competitive endogenous RNA reveals the function of circRNAs in osteosarcoma

Construction of a novel gene-based model for prognosis prediction of clear cell renal cell carcinoma

Expression profile analysis identifies key genes as prognostic markers for metastasis of osteosarcoma

LINC00908 negatively regulates microRNA-483-5p to increase TSPYL5 expression and inhibit the development of prostate cancer

miR-138-5p inhibits the malignant progression of prostate cancer by targeting FOXC1

Autophagy regulation using luteolin: new insight into its anti-tumor activity

Keynote webinar | Spotlight on antibody–drug conjugates in cancer